Celldex Therapeutics, Inc. (CLDX) 10-Year Financial Performance & Capital Metrics

CLDX •

HealthcareBiotechnologyDrug Discovery and Antibody Platforms

AboutCelldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.Show more

Revenue $2M -78.6%
EBITDA -$284M -48.0%
Net Income -$259M -63.9%
EPS (Diluted) -3.90 -59.2%
Gross Margin 100% +104.5%
EBITDA Margin -18934.67% -592.7%
Operating Margin -19160% -589.5%
Net Margin -17253.33% -667.2%
ROE -40.62% -51.3%
ROIC -35.25% -34.8%
Debt/Equity 0.00 -13.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading near 52-week high

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Sales declining 27.4% over 5 years
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-12.15%

5Y-27.36%

3Y-13.98%

TTM-78.63%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-63.94%

EPS CAGR

10Y-

5Y-

3Y-

TTM-59.18%

ROCE

10Y Avg-40.26%

5Y Avg-33.99%

3Y Avg-39.27%

Latest-44.74%

Peer Comparison

Drug Discovery and Antibody Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
REGNRegeneron Pharmaceuticals, Inc.	107.56B	781.67	18.84	0.99%	31.41%	14.41%	3.79%	0.09
CTMXCytomX Therapeutics, Inc.	430.14M	5.37	14.13	36.45%	24.66%	26.09%
PRTCPureTech Health plc	405.3M	16.77	8.39	44.98%	-495.91%	-8.53%		0.05
DNAGinkgo Bioworks Holdings, Inc.	327.53M	6.75	-1.20	-25.06%	-183.81%	-61.5%		0.82
BCYCBicycle Therapeutics plc	111.38M	5.73	-1.98	30.76%	-8.85%	-40.53%		0.01
CCCCC4 Therapeutics, Inc.	261.67M	2.70	-2.13	-100%		-40.92%		0.23
MOLNMolecular Partners AG	187.84M	5.02	-2.43	-29.38%	-10.87%	-63.06%		0.02
RXRXRecursion Pharmaceuticals, Inc.	1.94B	3.67	-2.55	26.92%	-8.65%	-57.01%		0.07

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	6.79M	12.74M	9.54M	3.57M	7.42M	4.65M	2.36M	6.88M	7.02M	1.5M
Revenue Growth %	23.83%	87.78%	-25.15%	-62.54%	107.61%	-37.3%	-49.32%	192.02%	1.99%	-78.63%
Cost of Goods Sold+	102.03M	96.17M	66.45M	42.67M	42.53M	53.31M	82.26M	118.01M	163.55M	0
COGS % of Revenue	1503.48%	754.7%	696.68%	1194.29%	573.39%	1146.23%	3489.94%	1714.53%	2329.77%	-
Gross Profit+	-95.24M	-83.43M	-56.91M	-39.1M	-35.12M	-48.66M	-79.9M	-111.13M	-156.53M	1.5M
Gross Margin %	-1403.48%	-654.7%	-596.68%	-1094.29%	-473.39%	-1046.23%	-3389.94%	-1614.53%	-2229.77%	100%
Gross Profit Growth %	-6583.32%	12.4%	31.78%	31.3%	10.19%	-38.57%	-64.2%	-39.08%	-40.86%	100.96%
Operating Expenses+	37.68M	38.1M	99.53M	15.93M	28.24M	22.58M	35.33M	43.41M	38.55M	288.9M
OpEx % of Revenue	555.2%	298.98%	1043.46%	445.9%	380.67%	485.55%	1499.07%	630.74%	549.12%	19260%
Selling, General & Admin	35.98M	25M	19.27M	15.43M	14.46M	20.49M	27.2M	30.91M	38.55M	43.8M
SG&A % of Revenue	530.19%	196.21%	202.02%	431.74%	194.88%	440.51%	1153.8%	449.14%	549.12%	2920%
Research & Development	102.73M	96.17M	66.45M	42.67M	40.53M	56.81M	82.26M	118.01M	163.55M	245.1M
R&D % of Revenue	1513.79%	754.7%	696.68%	1194.29%	546.43%	1221.48%	3489.94%	1714.53%	2329.77%	16340%
Other Operating Expenses	-101.03M	-83.08M	13.81M	-42.17M	-26.75M	-54.72M	-74.12M	-105.51M	-163.55M	0
Operating Income+	-132.92M	-121.53M	-156.44M	-55.03M	-63.35M	-71.24M	-115.23M	-154.54M	-195.08M	-287.4M
Operating Margin %	-1958.68%	-953.68%	-1640.13%	-1540.19%	-854.06%	-1531.78%	-4889.01%	-2245.27%	-2778.89%	-19160%
Operating Income Growth %	-2.61%	8.57%	-28.73%	64.82%	-15.12%	-12.45%	-61.75%	-34.11%	-26.23%	-47.33%
EBITDA+	-128.82M	-116.22M	-152.63M	-50.17M	-59.42M	-68.17M	-112.34M	-151.53M	-191.9M	-284.02M
EBITDA Margin %	-1898.38%	-912.01%	-1600.28%	-1404.23%	-801.09%	-1465.81%	-4766.14%	-2201.57%	-2733.63%	-18934.67%
EBITDA Growth %	-2.62%	9.79%	-31.34%	67.13%	-18.44%	-14.72%	-64.78%	-34.89%	-26.64%	-48%
D&A (Non-Cash Add-back)	4.09M	5.31M	3.8M	4.86M	3.93M	3.07M	2.9M	3.01M	3.18M	3.38M
EBIT	-128.53M	-109.33M	-76.4M	-54.52M	-49.57M	-69.15M	-107.1M	-142.04M	-195.08M	-287.4M
Net Interest Income+	4.39M	4.21M	4.49M	4.15M	2.41M	505K	2.91M	13.11M	37.22M	28.61M
Interest Income	4.39M	4.21M	4.49M	4.15M	2.41M	505K	2.91M	13.11M	37.22M	28.61M
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	4.39M	4.21M	4.49M	4.15M	2.41M	505K	2.91M	13.11M	37.22M	28.6M
Pretax Income+	-128.53M	-117.31M	-151.95M	-50.88M	-60.95M	-70.74M	-112.33M	-141.43M	-157.86M	-258.8M
Pretax Margin %	-1894.05%	-920.61%	-1593.09%	-1423.96%	-821.61%	-1520.92%	-4765.59%	-2054.76%	-2248.76%	-17253.33%
Income Tax+	0	-24.28M	-765K	0	-1.17M	-227K	0	0	0	0
Effective Tax Rate %	100%	79.3%	99.5%	100%	98.09%	99.68%	100%	100%	100%	100%
Net Income+	-128.53M	-93.03M	-151.18M	-50.88M	-59.78M	-70.51M	-112.33M	-141.43M	-157.86M	-258.8M
Net Margin %	-1894.05%	-730.06%	-1585.07%	-1423.96%	-805.88%	-1516.04%	-4765.59%	-2054.76%	-2248.76%	-17253.33%
Net Income Growth %	-1.05%	27.62%	-62.51%	66.35%	-17.5%	-17.95%	-59.3%	-25.91%	-11.62%	-63.94%
Net Income (Continuing)	-128.53M	-93.03M	-151.18M	-50.88M	-59.78M	-70.51M	-112.33M	-141.43M	-157.86M	-258.8M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-18.99	-10.86	-14.48	-3.51	-2.02	-1.64	-2.40	-2.92	-2.45	-3.90
EPS Growth %	3.41%	42.81%	-33.33%	75.76%	42.45%	18.81%	-46.34%	-21.67%	16.1%	-59.18%
EPS (Basic)	-18.99	-10.86	-14.48	-3.51	-2.02	-1.64	-2.40	-2.92	-2.45	-3.90
Diluted Shares Outstanding	6.77M	8.57M	10.44M	14.51M	29.64M	42.87M	46.89M	48.45M	64.39M	66.5M
Basic Shares Outstanding	6.77M	8.57M	10.44M	14.51M	29.64M	42.87M	46.89M	48.45M	64.39M	66.5M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	195.57M	144.76M	99.08M	66.7M	197.84M	410.84M	317.69M	431.69M	747.16M	534.66M
Cash & Short-Term Investments	189.78M	139.43M	94.02M	64.18M	194.42M	408.25M	304.95M	421.7M	725.28M	518.57M
Cash Only	42.46M	40.29M	24.31M	11.23M	43.84M	39.14M	29.43M	34.81M	28.36M	28.87M
Short-Term Investments	147.31M	99.14M	69.71M	52.95M	150.59M	369.11M	275.52M	386.88M	696.92M	489.7M
Accounts Receivable	1.78M	1.88M	3.16M	1.22M	1.8M	172K	347K	4.53M	700K	2.02M
Days Sales Outstanding	95.96	53.85	121	124.12	88.67	13.5	53.74	240.12	36.4	490.32
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	5.47M	21.18M	14.08M
Total Non-Current Assets+	187.79M	170.87M	56.73M	56.23M	37.99M	33.81M	35.04M	33.93M	45.18M	48.32M
Property, Plant & Equipment	13.19M	10.37M	6.11M	7.5M	7.26M	6.52M	7.75M	6.64M	8.24M	7.77M
Fixed Asset Turnover	0.51x	1.23x	1.56x	0.48x	1.02x	0.71x	0.30x	1.04x	0.85x	0.19x
Goodwill	90.98M	90.98M	0	0	0	0	0	0	0	0
Intangible Assets	81.49M	67.59M	50.62M	48.69M	30.69M	27.19M	27.19M	27.19M	27.19M	27.19M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	2.13M	3.73M	3.73M	41K	41K	104K	104K	107K	9.75M	13.36M
Total Assets+	383.36M	315.62M	155.81M	122.93M	235.84M	444.65M	352.74M	465.63M	792.34M	582.98M
Asset Turnover	0.02x	0.04x	0.06x	0.03x	0.03x	0.01x	0.01x	0.01x	0.01x	0.00x
Asset Growth %	13.56%	-17.67%	-50.63%	-21.1%	91.84%	88.54%	-20.67%	32%	70.17%	-26.42%
Total Current Liabilities+	35.22M	27.74M	12.6M	11.64M	14.21M	16.53M	18.61M	31.13M	39.5M	50.99M
Accounts Payable	1.74M	1.72M	1.07M	1.17M	1.05M	1.23M	3.34M	3.49M	3.27M	1.18M
Days Payables Outstanding	6.22	6.51	5.87	10.04	8.99	8.41	14.82	10.81	7.29	-
Short-Term Debt	0	6.57M	4.53M	1.94M	0	0	0	0	0	1.55M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	26.35M	0	0	2.01M	3.37M	1.55M	990K	3.99M	942K	48.26M
Current Ratio	5.55x	5.22x	7.86x	5.73x	13.93x	24.86x	17.07x	13.87x	18.91x	10.49x
Quick Ratio	5.55x	5.22x	7.86x	5.73x	13.93x	24.86x	17.07x	13.87x	18.91x	10.49x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	82.7M	51.52M	19.15M	17.26M	12.28M	8.65M	7.92M	5.33M	5.83M	4.83M
Long-Term Debt	0	0	0	0	0	0	0	0	0	784K
Capital Lease Obligations	0	0	0	1.71M	2.15M	1.3M	2.59M	928K	2.36M	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	82.7M	51.52M	19.15M	15.55M	10.12M	7.35M	5.33M	4.4M	3.47M	4.04M
Total Liabilities	117.93M	79.25M	31.75M	28.91M	26.48M	25.18M	26.53M	36.46M	45.34M	55.82M
Total Debt+	0	6.57M	4.53M	3.66M	3.48M	3.04M	4.03M	2.54M	3.81M	2.34M
Net Debt	-42.46M	-33.72M	-19.78M	-7.58M	-40.35M	-36.1M	-25.4M	-32.27M	-24.54M	-26.54M
Debt / Equity	-	0.03x	0.04x	0.04x	0.02x	0.01x	0.01x	0.01x	0.01x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	265.43M	236.37M	124.06M	94.03M	209.36M	419.48M	326.2M	429.17M	747M	527.16M
Equity Growth %	-8.51%	-10.95%	-47.51%	-24.21%	122.66%	100.36%	-22.24%	31.57%	74.06%	-29.43%
Book Value per Share	39.21	27.58	11.88	6.48	7.06	9.78	6.96	8.86	11.60	7.93
Total Shareholders' Equity	265.43M	236.37M	124.06M	94.03M	209.36M	419.48M	326.2M	429.17M	747M	527.16M
Common Stock	121K	139K	12K	17K	40K	47K	47K	56K	66K	67K
Retained Earnings	-719.49M	-812.52M	-962.44M	-1.01B	-1.07B	-1.14B	-1.26B	-1.4B	-1.56B	-1.81B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	2.54M	2.56M	2.58M	2.62M	2.59M	1.89M	1.26M	3.31M	3.31M	3.63M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	-113.04M	-99.93M	-75.23M	-46.41M	-40.4M	-60.91M	-103.73M	-107.29M	-157.78M	-210.94M
Operating CF Margin %	-1665.72%	-784.2%	-788.79%	-1299.05%	-544.68%	-1309.59%	-4401.02%	-1558.78%	-2247.55%	-14063%
Operating CF Growth %	-14.31%	11.59%	24.71%	38.31%	12.95%	-50.75%	-70.31%	-3.43%	-47.06%	-33.7%
Net Income	-128.53M	-93.03M	-151.18M	-50.88M	-59.78M	-70.51M	-112.33M	-141.43M	-157.86M	-258.76M
Depreciation & Amortization	4.09M	5.31M	3.8M	4.86M	3.93M	3.07M	1.4M	3.01M	3.18M	-2.48M
Stock-Based Compensation	15.32M	12.31M	8.08M	4.55M	3.92M	8.95M	0	23.89M	34.24M	36.22M
Deferred Taxes	1.01M	-24.28M	-765K	671K	-1.17M	-227K	0	0	0	0
Other Non-Cash Items	1.64M	11.96M	80.2M	-1.29M	13M	-1.14M	11.09M	-6.22M	-15.73M	14.07M
Working Capital Changes	-6.56M	-12.21M	-15.37M	-4.32M	-299K	-1.05M	-3.9M	13.46M	-21.6M	0
Change in Receivables	-814K	-96K	-777K	-777K	-787K	1.57M	-175K	-2.28M	1.93M	-1.31M
Change in Inventory	-687K	-3.57M	1.78M	13.89M	0	0	0	0	0	0
Change in Payables	-4.97M	-8.74M	-13.11M	-13.11M	1.64M	3.65M	3.12M	9.38M	11.63M	11.03M
Cash from Investing+	68.91M	46.47M	29.82M	17.08M	-98.22M	-216.16M	89.94M	-105.78M	-290.13M	209.07M
Capital Expenditures	-2.75M	-1.79M	-813K	-731K	-1.55M	-1.25M	-1.83M	-1.82M	-1.92M	0
CapEx % of Revenue	40.54%	14.03%	8.52%	20.46%	20.92%	26.85%	77.56%	26.41%	27.34%	-
Acquisitions	4.59M	1.79M	342K	20K	55K	27K	69K	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-1.79M	0	0	0	0	0	0	0	-2.71M
Cash from Financing+	14.48M	51.29M	29.44M	16.26M	171.23M	272.37M	4.08M	218.46M	441.45M	2.39M
Debt Issued (Net)	0	0	0	0	0	0	0	0	0	0
Equity Issued (Net)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	0
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0	0	0
Other Financing	536K	265K	419K	9K	434K	2.48M	0	2.24M	9.15M	2.39M
Net Change in Cash	-29.65M	-2.17M	-15.98M	-13.08M	32.6M	-4.69M	-9.71M	5.38M	-6.46M	515K
Free Cash Flow+	-115.79M	-101.72M	-76.05M	-47.15M	-41.96M	-62.16M	-105.56M	-109.11M	-159.7M	-210.94M
FCF Margin %	-1706.26%	-798.23%	-797.32%	-1319.51%	-565.6%	-1336.44%	-4478.57%	-1585.2%	-2274.89%	-14063%
FCF Growth %	-11.59%	12.15%	25.24%	38%	11.01%	-48.15%	-69.83%	-3.36%	-46.36%	-32.09%
FCF per Share	-17.11	-11.87	-7.28	-3.25	-1.42	-1.45	-2.25	-2.25	-2.48	-3.17
FCF Conversion (FCF/Net Income)	0.88x	1.07x	0.50x	0.91x	0.68x	0.86x	0.92x	0.76x	1.00x	0.82x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-46.27%	-37.08%	-83.89%	-46.66%	-39.41%	-22.43%	-30.13%	-37.45%	-26.84%	-40.62%
Return on Invested Capital (ROIC)	-44.76%	-42.83%	-76.45%	-43.28%	-37.2%	-19.35%	-25.26%	-33.23%	-26.14%	-35.25%
Gross Margin	-1403.48%	-654.7%	-596.68%	-1094.29%	-473.39%	-1046.23%	-3389.94%	-1614.53%	-2229.77%	100%
Net Margin	-1894.05%	-730.06%	-1585.07%	-1423.96%	-805.88%	-1516.04%	-4765.59%	-2054.76%	-2248.76%	-17253.33%
Debt / Equity	-	0.03x	0.04x	0.04x	0.02x	0.01x	0.01x	0.01x	0.01x	0.00x
FCF Conversion	0.88x	1.07x	0.50x	0.91x	0.68x	0.86x	0.92x	0.76x	1.00x	0.82x
Revenue Growth	23.83%	87.78%	-25.15%	-62.54%	107.61%	-37.3%	-49.32%	192.02%	1.99%	-78.63%

US Stock Screener

...

Celldex Therapeutics, Inc. (CLDX) 10-Year Financial Performance & Capital Metrics

CLDX •

HealthcareBiotechnologyDrug Discovery and Antibody Platforms

Revenue $2M -78.6%
EBITDA -$284M -48.0%
Net Income -$259M -63.9%
EPS (Diluted) -3.90 -59.2%
Gross Margin 100% +104.5%
EBITDA Margin -18934.67% -592.7%
Operating Margin -19160% -589.5%
Net Margin -17253.33% -667.2%
ROE -40.62% -51.3%
ROIC -35.25% -34.8%
Debt/Equity 0.00 -13.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading near 52-week high

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Sales declining 27.4% over 5 years
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-12.15%

5Y-27.36%

3Y-13.98%

TTM-78.63%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-63.94%

EPS CAGR

10Y-

5Y-

3Y-

TTM-59.18%

ROCE

10Y Avg-40.26%

5Y Avg-33.99%

3Y Avg-39.27%

Latest-44.74%

Peer Comparison

Drug Discovery and Antibody Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
REGNRegeneron Pharmaceuticals, Inc.	107.56B	781.67	18.84	0.99%	31.41%	14.41%	3.79%	0.09
CTMXCytomX Therapeutics, Inc.	430.14M	5.37	14.13	36.45%	24.66%	26.09%
PRTCPureTech Health plc	405.3M	16.77	8.39	44.98%	-495.91%	-8.53%		0.05
DNAGinkgo Bioworks Holdings, Inc.	327.53M	6.75	-1.20	-25.06%	-183.81%	-61.5%		0.82
BCYCBicycle Therapeutics plc	111.38M	5.73	-1.98	30.76%	-8.85%	-40.53%		0.01
CCCCC4 Therapeutics, Inc.	261.67M	2.70	-2.13	-100%		-40.92%		0.23
MOLNMolecular Partners AG	187.84M	5.02	-2.43	-29.38%	-10.87%	-63.06%		0.02
RXRXRecursion Pharmaceuticals, Inc.	1.94B	3.67	-2.55	26.92%	-8.65%	-57.01%		0.07

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	6.79M	12.74M	9.54M	3.57M	7.42M	4.65M	2.36M	6.88M	7.02M	1.5M
Revenue Growth %	23.83%	87.78%	-25.15%	-62.54%	107.61%	-37.3%	-49.32%	192.02%	1.99%	-78.63%
Cost of Goods Sold+	102.03M	96.17M	66.45M	42.67M	42.53M	53.31M	82.26M	118.01M	163.55M	0
COGS % of Revenue	1503.48%	754.7%	696.68%	1194.29%	573.39%	1146.23%	3489.94%	1714.53%	2329.77%	-
Gross Profit+	-95.24M	-83.43M	-56.91M	-39.1M	-35.12M	-48.66M	-79.9M	-111.13M	-156.53M	1.5M
Gross Margin %	-1403.48%	-654.7%	-596.68%	-1094.29%	-473.39%	-1046.23%	-3389.94%	-1614.53%	-2229.77%	100%
Gross Profit Growth %	-6583.32%	12.4%	31.78%	31.3%	10.19%	-38.57%	-64.2%	-39.08%	-40.86%	100.96%
Operating Expenses+	37.68M	38.1M	99.53M	15.93M	28.24M	22.58M	35.33M	43.41M	38.55M	288.9M
OpEx % of Revenue	555.2%	298.98%	1043.46%	445.9%	380.67%	485.55%	1499.07%	630.74%	549.12%	19260%
Selling, General & Admin	35.98M	25M	19.27M	15.43M	14.46M	20.49M	27.2M	30.91M	38.55M	43.8M
SG&A % of Revenue	530.19%	196.21%	202.02%	431.74%	194.88%	440.51%	1153.8%	449.14%	549.12%	2920%
Research & Development	102.73M	96.17M	66.45M	42.67M	40.53M	56.81M	82.26M	118.01M	163.55M	245.1M
R&D % of Revenue	1513.79%	754.7%	696.68%	1194.29%	546.43%	1221.48%	3489.94%	1714.53%	2329.77%	16340%
Other Operating Expenses	-101.03M	-83.08M	13.81M	-42.17M	-26.75M	-54.72M	-74.12M	-105.51M	-163.55M	0
Operating Income+	-132.92M	-121.53M	-156.44M	-55.03M	-63.35M	-71.24M	-115.23M	-154.54M	-195.08M	-287.4M
Operating Margin %	-1958.68%	-953.68%	-1640.13%	-1540.19%	-854.06%	-1531.78%	-4889.01%	-2245.27%	-2778.89%	-19160%
Operating Income Growth %	-2.61%	8.57%	-28.73%	64.82%	-15.12%	-12.45%	-61.75%	-34.11%	-26.23%	-47.33%
EBITDA+	-128.82M	-116.22M	-152.63M	-50.17M	-59.42M	-68.17M	-112.34M	-151.53M	-191.9M	-284.02M
EBITDA Margin %	-1898.38%	-912.01%	-1600.28%	-1404.23%	-801.09%	-1465.81%	-4766.14%	-2201.57%	-2733.63%	-18934.67%
EBITDA Growth %	-2.62%	9.79%	-31.34%	67.13%	-18.44%	-14.72%	-64.78%	-34.89%	-26.64%	-48%
D&A (Non-Cash Add-back)	4.09M	5.31M	3.8M	4.86M	3.93M	3.07M	2.9M	3.01M	3.18M	3.38M
EBIT	-128.53M	-109.33M	-76.4M	-54.52M	-49.57M	-69.15M	-107.1M	-142.04M	-195.08M	-287.4M
Net Interest Income+	4.39M	4.21M	4.49M	4.15M	2.41M	505K	2.91M	13.11M	37.22M	28.61M
Interest Income	4.39M	4.21M	4.49M	4.15M	2.41M	505K	2.91M	13.11M	37.22M	28.61M
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	4.39M	4.21M	4.49M	4.15M	2.41M	505K	2.91M	13.11M	37.22M	28.6M
Pretax Income+	-128.53M	-117.31M	-151.95M	-50.88M	-60.95M	-70.74M	-112.33M	-141.43M	-157.86M	-258.8M
Pretax Margin %	-1894.05%	-920.61%	-1593.09%	-1423.96%	-821.61%	-1520.92%	-4765.59%	-2054.76%	-2248.76%	-17253.33%
Income Tax+	0	-24.28M	-765K	0	-1.17M	-227K	0	0	0	0
Effective Tax Rate %	100%	79.3%	99.5%	100%	98.09%	99.68%	100%	100%	100%	100%
Net Income+	-128.53M	-93.03M	-151.18M	-50.88M	-59.78M	-70.51M	-112.33M	-141.43M	-157.86M	-258.8M
Net Margin %	-1894.05%	-730.06%	-1585.07%	-1423.96%	-805.88%	-1516.04%	-4765.59%	-2054.76%	-2248.76%	-17253.33%
Net Income Growth %	-1.05%	27.62%	-62.51%	66.35%	-17.5%	-17.95%	-59.3%	-25.91%	-11.62%	-63.94%
Net Income (Continuing)	-128.53M	-93.03M	-151.18M	-50.88M	-59.78M	-70.51M	-112.33M	-141.43M	-157.86M	-258.8M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-18.99	-10.86	-14.48	-3.51	-2.02	-1.64	-2.40	-2.92	-2.45	-3.90
EPS Growth %	3.41%	42.81%	-33.33%	75.76%	42.45%	18.81%	-46.34%	-21.67%	16.1%	-59.18%
EPS (Basic)	-18.99	-10.86	-14.48	-3.51	-2.02	-1.64	-2.40	-2.92	-2.45	-3.90
Diluted Shares Outstanding	6.77M	8.57M	10.44M	14.51M	29.64M	42.87M	46.89M	48.45M	64.39M	66.5M
Basic Shares Outstanding	6.77M	8.57M	10.44M	14.51M	29.64M	42.87M	46.89M	48.45M	64.39M	66.5M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	195.57M	144.76M	99.08M	66.7M	197.84M	410.84M	317.69M	431.69M	747.16M	534.66M
Cash & Short-Term Investments	189.78M	139.43M	94.02M	64.18M	194.42M	408.25M	304.95M	421.7M	725.28M	518.57M
Cash Only	42.46M	40.29M	24.31M	11.23M	43.84M	39.14M	29.43M	34.81M	28.36M	28.87M
Short-Term Investments	147.31M	99.14M	69.71M	52.95M	150.59M	369.11M	275.52M	386.88M	696.92M	489.7M
Accounts Receivable	1.78M	1.88M	3.16M	1.22M	1.8M	172K	347K	4.53M	700K	2.02M
Days Sales Outstanding	95.96	53.85	121	124.12	88.67	13.5	53.74	240.12	36.4	490.32
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	5.47M	21.18M	14.08M
Total Non-Current Assets+	187.79M	170.87M	56.73M	56.23M	37.99M	33.81M	35.04M	33.93M	45.18M	48.32M
Property, Plant & Equipment	13.19M	10.37M	6.11M	7.5M	7.26M	6.52M	7.75M	6.64M	8.24M	7.77M
Fixed Asset Turnover	0.51x	1.23x	1.56x	0.48x	1.02x	0.71x	0.30x	1.04x	0.85x	0.19x
Goodwill	90.98M	90.98M	0	0	0	0	0	0	0	0
Intangible Assets	81.49M	67.59M	50.62M	48.69M	30.69M	27.19M	27.19M	27.19M	27.19M	27.19M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	2.13M	3.73M	3.73M	41K	41K	104K	104K	107K	9.75M	13.36M
Total Assets+	383.36M	315.62M	155.81M	122.93M	235.84M	444.65M	352.74M	465.63M	792.34M	582.98M
Asset Turnover	0.02x	0.04x	0.06x	0.03x	0.03x	0.01x	0.01x	0.01x	0.01x	0.00x
Asset Growth %	13.56%	-17.67%	-50.63%	-21.1%	91.84%	88.54%	-20.67%	32%	70.17%	-26.42%
Total Current Liabilities+	35.22M	27.74M	12.6M	11.64M	14.21M	16.53M	18.61M	31.13M	39.5M	50.99M
Accounts Payable	1.74M	1.72M	1.07M	1.17M	1.05M	1.23M	3.34M	3.49M	3.27M	1.18M
Days Payables Outstanding	6.22	6.51	5.87	10.04	8.99	8.41	14.82	10.81	7.29	-
Short-Term Debt	0	6.57M	4.53M	1.94M	0	0	0	0	0	1.55M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	26.35M	0	0	2.01M	3.37M	1.55M	990K	3.99M	942K	48.26M
Current Ratio	5.55x	5.22x	7.86x	5.73x	13.93x	24.86x	17.07x	13.87x	18.91x	10.49x
Quick Ratio	5.55x	5.22x	7.86x	5.73x	13.93x	24.86x	17.07x	13.87x	18.91x	10.49x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	82.7M	51.52M	19.15M	17.26M	12.28M	8.65M	7.92M	5.33M	5.83M	4.83M
Long-Term Debt	0	0	0	0	0	0	0	0	0	784K
Capital Lease Obligations	0	0	0	1.71M	2.15M	1.3M	2.59M	928K	2.36M	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	82.7M	51.52M	19.15M	15.55M	10.12M	7.35M	5.33M	4.4M	3.47M	4.04M
Total Liabilities	117.93M	79.25M	31.75M	28.91M	26.48M	25.18M	26.53M	36.46M	45.34M	55.82M
Total Debt+	0	6.57M	4.53M	3.66M	3.48M	3.04M	4.03M	2.54M	3.81M	2.34M
Net Debt	-42.46M	-33.72M	-19.78M	-7.58M	-40.35M	-36.1M	-25.4M	-32.27M	-24.54M	-26.54M
Debt / Equity	-	0.03x	0.04x	0.04x	0.02x	0.01x	0.01x	0.01x	0.01x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	265.43M	236.37M	124.06M	94.03M	209.36M	419.48M	326.2M	429.17M	747M	527.16M
Equity Growth %	-8.51%	-10.95%	-47.51%	-24.21%	122.66%	100.36%	-22.24%	31.57%	74.06%	-29.43%
Book Value per Share	39.21	27.58	11.88	6.48	7.06	9.78	6.96	8.86	11.60	7.93
Total Shareholders' Equity	265.43M	236.37M	124.06M	94.03M	209.36M	419.48M	326.2M	429.17M	747M	527.16M
Common Stock	121K	139K	12K	17K	40K	47K	47K	56K	66K	67K
Retained Earnings	-719.49M	-812.52M	-962.44M	-1.01B	-1.07B	-1.14B	-1.26B	-1.4B	-1.56B	-1.81B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	2.54M	2.56M	2.58M	2.62M	2.59M	1.89M	1.26M	3.31M	3.31M	3.63M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	-113.04M	-99.93M	-75.23M	-46.41M	-40.4M	-60.91M	-103.73M	-107.29M	-157.78M	-210.94M
Operating CF Margin %	-1665.72%	-784.2%	-788.79%	-1299.05%	-544.68%	-1309.59%	-4401.02%	-1558.78%	-2247.55%	-14063%
Operating CF Growth %	-14.31%	11.59%	24.71%	38.31%	12.95%	-50.75%	-70.31%	-3.43%	-47.06%	-33.7%
Net Income	-128.53M	-93.03M	-151.18M	-50.88M	-59.78M	-70.51M	-112.33M	-141.43M	-157.86M	-258.76M
Depreciation & Amortization	4.09M	5.31M	3.8M	4.86M	3.93M	3.07M	1.4M	3.01M	3.18M	-2.48M
Stock-Based Compensation	15.32M	12.31M	8.08M	4.55M	3.92M	8.95M	0	23.89M	34.24M	36.22M
Deferred Taxes	1.01M	-24.28M	-765K	671K	-1.17M	-227K	0	0	0	0
Other Non-Cash Items	1.64M	11.96M	80.2M	-1.29M	13M	-1.14M	11.09M	-6.22M	-15.73M	14.07M
Working Capital Changes	-6.56M	-12.21M	-15.37M	-4.32M	-299K	-1.05M	-3.9M	13.46M	-21.6M	0
Change in Receivables	-814K	-96K	-777K	-777K	-787K	1.57M	-175K	-2.28M	1.93M	-1.31M
Change in Inventory	-687K	-3.57M	1.78M	13.89M	0	0	0	0	0	0
Change in Payables	-4.97M	-8.74M	-13.11M	-13.11M	1.64M	3.65M	3.12M	9.38M	11.63M	11.03M
Cash from Investing+	68.91M	46.47M	29.82M	17.08M	-98.22M	-216.16M	89.94M	-105.78M	-290.13M	209.07M
Capital Expenditures	-2.75M	-1.79M	-813K	-731K	-1.55M	-1.25M	-1.83M	-1.82M	-1.92M	0
CapEx % of Revenue	40.54%	14.03%	8.52%	20.46%	20.92%	26.85%	77.56%	26.41%	27.34%	-
Acquisitions	4.59M	1.79M	342K	20K	55K	27K	69K	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-1.79M	0	0	0	0	0	0	0	-2.71M
Cash from Financing+	14.48M	51.29M	29.44M	16.26M	171.23M	272.37M	4.08M	218.46M	441.45M	2.39M
Debt Issued (Net)	0	0	0	0	0	0	0	0	0	0
Equity Issued (Net)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	0
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0	0	0
Other Financing	536K	265K	419K	9K	434K	2.48M	0	2.24M	9.15M	2.39M
Net Change in Cash	-29.65M	-2.17M	-15.98M	-13.08M	32.6M	-4.69M	-9.71M	5.38M	-6.46M	515K
Free Cash Flow+	-115.79M	-101.72M	-76.05M	-47.15M	-41.96M	-62.16M	-105.56M	-109.11M	-159.7M	-210.94M
FCF Margin %	-1706.26%	-798.23%	-797.32%	-1319.51%	-565.6%	-1336.44%	-4478.57%	-1585.2%	-2274.89%	-14063%
FCF Growth %	-11.59%	12.15%	25.24%	38%	11.01%	-48.15%	-69.83%	-3.36%	-46.36%	-32.09%
FCF per Share	-17.11	-11.87	-7.28	-3.25	-1.42	-1.45	-2.25	-2.25	-2.48	-3.17
FCF Conversion (FCF/Net Income)	0.88x	1.07x	0.50x	0.91x	0.68x	0.86x	0.92x	0.76x	1.00x	0.82x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-46.27%	-37.08%	-83.89%	-46.66%	-39.41%	-22.43%	-30.13%	-37.45%	-26.84%	-40.62%
Return on Invested Capital (ROIC)	-44.76%	-42.83%	-76.45%	-43.28%	-37.2%	-19.35%	-25.26%	-33.23%	-26.14%	-35.25%
Gross Margin	-1403.48%	-654.7%	-596.68%	-1094.29%	-473.39%	-1046.23%	-3389.94%	-1614.53%	-2229.77%	100%
Net Margin	-1894.05%	-730.06%	-1585.07%	-1423.96%	-805.88%	-1516.04%	-4765.59%	-2054.76%	-2248.76%	-17253.33%
Debt / Equity	-	0.03x	0.04x	0.04x	0.02x	0.01x	0.01x	0.01x	0.01x	0.00x
FCF Conversion	0.88x	1.07x	0.50x	0.91x	0.68x	0.86x	0.92x	0.76x	1.00x	0.82x
Revenue Growth	23.83%	87.78%	-25.15%	-62.54%	107.61%	-37.3%	-49.32%	192.02%	1.99%	-78.63%

Celldex Therapeutics, Inc. (CLDX) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare CLDX vs Peers

vs REGN

vs CNTA

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Celldex Therapeutics, Inc. (CLDX) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare CLDX vs Peers

vs REGN

vs CNTA

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios